| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Autoantibodies in lupus: Culprits or passive bystanders?
|
Rekvig, Ole P.
|
|
2012
|
11 |
8 |
p. 596-603
8 p.
|
artikel
|
| 2 |
Controversies in rheumatism and autoimmunity
|
Doria, Andrea
|
|
2012
|
11 |
8 |
p. 555-557
3 p.
|
artikel
|
| 3 |
Does seronegative antiphospholipid syndrome really exist?
|
Cervera, Ricard
|
|
2012
|
11 |
8 |
p. 581-584
4 p.
|
artikel
|
| 4 |
Early treatment in early undifferentiated arthritis
|
Olivieri, Ignazio
|
|
2012
|
11 |
8 |
p. 589-592
4 p.
|
artikel
|
| 5 |
Genes, epigenetic regulation and environmental factors: Which is the most relevant in developing autoimmune diseases?
|
Costenbader, Karen H.
|
|
2012
|
11 |
8 |
p. 604-609
6 p.
|
artikel
|
| 6 |
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’
|
Pengo, Vittorio
|
|
2012
|
11 |
8 |
p. 577-580
4 p.
|
artikel
|
| 7 |
Is fibromyalgia a discrete entity?
|
Ablin, Jacob N.
|
|
2012
|
11 |
8 |
p. 585-588
4 p.
|
artikel
|
| 8 |
Rituximab — Shadow, illusion or light?
|
van Vollenhoven, Ronald F.
|
|
2012
|
11 |
8 |
p. 563-567
5 p.
|
artikel
|
| 9 |
Systemic lupus erythematosus one disease or many?
|
Agmon-Levin, N.
|
|
2012
|
11 |
8 |
p. 593-595
3 p.
|
artikel
|
| 10 |
Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: “Pros” and “Cons”
|
Ceccarelli, Fulvia
|
|
2012
|
11 |
8 |
p. 568-571
4 p.
|
artikel
|
| 11 |
To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50
|
Buch, Maya H.
|
|
2012
|
11 |
8 |
p. 558-562
5 p.
|
artikel
|
| 12 |
Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment
|
Bijl, M.
|
|
2012
|
11 |
8 |
p. 572-576
5 p.
|
artikel
|
Tijdschrift beschrijving